

1 **The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a**
2 **Therapy Driven Route to High-Grade Transformation**

3

4 Samuel Backman¹, Johan Botling^{2,3}, Helena Nord², Suman Ghosal⁴, Peter Stålberg¹, C.

5 Christofer Juhlin⁵, Jonas Almlöf², Anders Sundin⁶, Liang Zhang⁷, Lotte Moens², Barbro

6 Eriksson⁷, Staffan Welin⁷, Per Hellman¹, Britt Skogseid⁷, Karel Pacak⁵, Kazhan

7 Mollazadegan⁷, Tobias Åkerström¹, Joakim Crona⁷

8

9 1 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

10 2 Department of Immunology, Genetics and Pathology and Science for Life Laboratory,
11 Uppsala University, Uppsala, Sweden

12 3 Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg,
13 Gothenburg, Sweden

14 4 Section on Medical Neuroendocrinology, *Eunice Kennedy Shriver* National Institute of
15 Child Health and Human Development, National Institutes of Health, 10 Center Drive,
16 Building 10, Room 1E-3140, Bethesda, MD, 20892, USA

17 5 Department of Oncology – Pathology, Karolinska Institutet, Stockholm, Sweden

18 6 Section of Radiology, Molecular Imaging, Department of Surgical Sciences, Uppsala
19 University, Uppsala, Sweden

20 7 Department of Medical Sciences, Uppsala University, Uppsala, Sweden

21

22

23 **Conflicts of interest:** The authors have no conflicts of interest to declare.

24 **Word count:** 3734

25 **Corresponding author:**

26 Joakim Crona

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 1 Joakim.crona@medsci.uu.se
- 2 +46186110000
- 3 Akademiska Sjukhuset ing 100
- 4 75185 Uppsala
- 5 Sweden

1 **Abstract**

2 Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of
3 disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular,
4 show frequent progression from a low/intermediate to a high-grade disease. To understand the
5 molecular mechanisms underlying this phenomenon, we performed multi-omics analysis of
6 32 longitudinal samples from six metastatic PanNET patients. Following MEN1 inactivation,
7 PanNETs exhibit genetic heterogeneity on both spatial and temporal dimensions with parallel
8 and convergent tumour evolution involving the *ATRX/DAXX* and mTOR pathways. Following
9 alkylating chemotherapy treatment, some PanNETs develop mismatch repair deficiency and
10 acquire a hypermutator phenotype. This DNA hypermutation phenotype was only found in
11 cases that also showed transformation into a high-grade PanNET. Overall, our findings
12 contribute to broaden the understanding of metastatic PanNET, and suggests that therapy
13 driven disease evolution is an important hallmark of this disease.

1 **Main**

2 Pancreatic neuroendocrine tumours (PanNETs) patients display extraordinary diverse disease
3 characteristics^{1,2}: This neoplasm may secrete various neuropeptides and demonstrate a wide
4 spectrum of invasiveness and cell proliferation that ranges from slowly growing localized
5 lesions, to rapidly dividing disseminated tumours^{3,4}. These factors are recognized as
6 prognostic markers determining the outcome from the disease. Further, many PanNET
7 patients experience evolving tumour characteristics over time with changes in hormone
8 secretion pattern and/or tumour grade. This evolutionary phenomenon is usually associated
9 with a very poor prognosis⁴⁻⁷. The underlying mechanisms leading to such changes in
10 PanNET biology are not understood.

11
12 The genetics of primary PanNET is well researched with mutations in *MEN1* as well as genes
13 related to mechanistic target of the rapamycin (mTOR) signalling pathway, and chromatin
14 remodelling (*ATRX/DAXX*) as major hallmarks^{8,9}. Somatic inactivation of *ATRX* and *DAXX*,
15 with subsequent activation of the alternative lengthening of telomeres phenotype, is suggested
16 to occur as secondary events in PanNETs¹⁰⁻¹². It was also shown that primary PanNETs with
17 loss of *DAXX*, *ATRX*, H3 lysine 36 trimethylation, *ARID1A*, and/or *CDKN2A* are
18 associated with shorter survival¹³. Pan-genomic data on metastatic PanNET is still lacking
19 and disease evolution has so far only been studied using targeted DNA sequencing: While
20 most PanNET appears to have stable genomic landscapes over time, some tumours may be
21 influenced by chemotherapy-associated mutagenesis¹³⁻¹⁵. As such, more information is clearly
22 needed to understand why PanNET may transform and acquire more aggressive traits. Hence,
23 we performed a detailed pan-molecular investigation of multiregional PanNET samples that
24 had been collected over the course of the disease, before and after treatment with systemic
25 therapies.

1 **Results**

2 To characterise the biology and evolution of metastatic and lethal PanNET we performed
3 multi-omics analysis of 32 primary and metastatic tumour samples representing 18 unique
4 lesions from 6 patients (Figure 1A, Supplementary Figure 1, Supplementary Tables 1-2). All
5 patients had metachronous samples with 19 collected at baseline and 13 at follow-up.
6 Tumours were WHO grade 1-2 at diagnosis and three patients had hormonal syndromes.
7 None fulfilled criteria for inherited tumour syndromes and all were negative for cancer-
8 associated pathogenic germline pathogenic variants (Supplementary materials). While two
9 patients had been exposed to systemic therapies before acquisition of baseline tumour
10 samples, all had been exposed to various PanNET approved systemic therapy regimens before
11 collection of follow-up tumour samples.

12

13 Genetic landscape and evolution in metastatic PanNET

14 Whole genome ($n=27$, median 67X) and whole exome ($n=5$, median 438X) DNA sequencing
15 revealed a genetic landscape representative of PanNET with pathogenic variants in
16 established disease drivers in all but one patient (Figure 1B, Supplementary Figures 2A-F,
17 Supplementary Tables 3 & 4). These results align with previous studies with four out of six
18 patients carrying somatic *MEN1* mutations, while somatic pathogenic variants in *ATRX*,
19 *DAXX* and the mTOR pathway were common auxiliary events. *MEN1* alterations were fully
20 clonal in 4/4 patients with remaining pathogenic variants in PanNET genes occurring in a
21 subclonal fashion: *ATRX/DAXX* 2/4 fully clonal, mTOR related genes 1/3 fully clonal and
22 chromatin integrity related genes (*ARID1A/SETD2*) 0/2 fully clonal (Supplementary Figures
23 3A-D). To further describe the evolutionary histories of PanNETs, we used these high
24 confidence substitutions and insertion-deletions to derive phylogenies, which showed
25 complex and heterogenous architectures: A monoclonal seeding pattern could be confirmed in

1 two patients that both had one distinct clone present in all metastases (Figures 2C and 3).
2 Contrary, PanNET04 displayed a polyclonal seeding pattern with two distinct metastatic
3 clones originating from separate parts of the primary tumour (Figure 3C). Here the two clones
4 showed evidence of convergent evolution on the mTOR pathway with parallel independent
5 truncating mutations in *DEPDC5* and *PTEN*. The tree topology of PanNET04 showed two
6 distinct branches, each containing both samples from the primary tumour and from metastatic
7 lesions. Such a branched evolution pattern could also be observed at the *ATRX/DAXX* loci: for
8 PanNET02 with different *ATRX* pathogenic variants in primary tumour and metastasis as well
9 as for PanNET03 with *ATRX* mutated primary tumour samples and a distinct *DAXX* mutation
10 observed in all samples from its metastases (Figures 2C and 3B). For two patients, whole
11 exome sequencing data was available from metastatic lesions: In PanNET05 all samples were
12 found to share pathogenic variants in *MEN1*, *DAXX* and *TSC2* while the two metastases from
13 PanNET06 had discordant mutation status for mutations in *TSC2* and *ARID1A*, which were
14 found in the baseline sample only (Figure 1B, Supplementary Figures 3E-F).
15 The tree topology based on small mutation data was largely concordant with the tree topology
16 resulting from DNA methylation data (Supplementary Table 4): In all cases we found a
17 striking similarity between the two reconstructions and clades of closely related samples
18 clustered together in the DNA methylation analyses (Figure 2D and Supplementary Figures
19 4A-H). On the cohort level, all tumour samples clustered together with other samples from the
20 same patient based on both DNA methylation and gene expression data (Supplementary
21 figures 5 and 6C).
22
23 In order to further characterize the evolution of metastatic PanNET we performed
24 computational inference of subclones using PyClone-VI that recapitulated the results from the
25 sample-level phylogenetic analysis (Figure 2E, Supplementary figures 7A-C). In PanNET01,

1 the primary tumour samples shared a subclonal cluster of mutations, believed to give rise to
2 the metastatic samples. The metastatic samples shared additional mutations not present in the
3 primary tumour. In PanNET02 and 03, the primary tumour samples shared a clonal cluster not
4 present in those from metastases, suggesting early metastatic seeding which predates the most
5 recent common ancestor of the primary tumours (Figures 2E and 3B). In PanNET04, parallel
6 metastatic seeding from different geographical regions of the primary tumour was observed,
7 with one of the primary tumour samples (Sample P1a) sharing a cluster with three samples
8 from a liver metastasis, while two other samples from the primary tumour shared mutation
9 clusters with a retroperitoneal lymph node metastasis (Figure 3C). A second liver metastasis
10 did not harbour either of these mutation clusters, suggesting seeding from a separate non-
11 sequenced part of the primary tumour, or prior to the establishment of the clones dominating
12 in the primary tumours.

13
14 Our results confirm that *MEN1* inactivation occurs very early in tumourigenesis, with
15 *ATRX/DAXX* being inactivated in subsequent steps. We then sought to determine the timing of
16 the conserved choreography of chromosomal mis-segregations previously described in
17 PanNETs, that has been linked to inactivated *ATRX/DAXX* leading to chromosomal cohesion
18 failure¹⁶. Patients PanNET03 and 04 had this chromosomal mis-segregation pattern, and by
19 performing binomial modelling based on tumour purity and ploidy as well as allele frequency
20 data we show that *ATRX/DAXX* mutations occurred before the whole genome doubling event
21 leading to copy number neutral loss of heterozygosity (Supplementary results). Moreover, we
22 were able to confirm that the major loss of heterozygosity events affect the same physical
23 chromosome across samples of the same patient (Supplementary figure 15). This is consistent
24 with one catastrophic event during tumour evolution, rather than multiple separate events
25 converging on the same copy number profile. These findings corroborate the evolutionary

1 model of PanNET where an islet cell inactivates *MEN1* as *the* tumour initiating event, and
2 that the tumour during its evolution may take different pathways. Inactivation of *ATRX/DAXX*
3 is commonly seen and followed by a complex pattern of chromosomal alterations that are
4 associated with aggressive tumour biology¹¹. Finally, alterations associated with the mTOR
5 signalling pathway and chromatin regulation often occur late in tumour development, similar
6 to observations across other cancers¹⁷.

7

8 Treatment induced DNA hypermutation

9 There was a clear trend towards increased tumour mutation burden (TMB) in metastases
10 compared to primary tumour samples. This was also noted in metachronous samples that had
11 been exposed to different PanNET approved therapies (Figure 1B): Five patients had been
12 treated in accordance with ENETS guidelines¹⁸ with the alkylating agents streptozocin or
13 temozolomide, and one (PanNET03) developed a hypermutation phenotype with a >100-fold
14 increase in TMB in the follow-up, compared to baseline samples. In order to examine the
15 mechanisms leading to this hypermutated state, we extracted *de novo* mutational signatures
16 from whole genome sequencing mutation sets. Here we identified that a majority of calls in
17 the hypermutated samples could be attributed to a mutation signature resembling SBS11,
18 which has been attributed to treatment with alkylating agents (Figure 4A-B, Supplementary
19 Figures 8A-G), and is characterized by C>T transversions. This signature was largely absent
20 from the non-hypermutated samples, whose mutations were attributed to a flat signature. This
21 finding was corroborated by fitting the mutation sets to COSMIC version 3 signatures
22 (Supplementary Figures 8H-I), the hypermutated samples from PanNET03 showed a majority
23 of mutations attributed to SBS11. The findings in the remaining samples overlapped with
24 primary PanNETs showing SBS 1, 5 and 8^{8,19}. This SBS11 signature was not present in
25 baseline samples of patient PanNET03, that had not been subjected to streptozocin treatment.

1 We therefore hypothesized that the SBS11-related hypermutation observed in tumour samples
2 of PanNET03 occurred secondary to treatment with streptozocin in the context of mismatch
3 repair deficiency (dMMR), as has been shown in glioblastoma^{20,21}.

4
5 In order to test the hypothesis that hypermutation is related to dMMR, we scrutinized the
6 hypermutated samples for evidence of damaging mutations in mismatch repair genes (Figure
7 4A, Supplementary table 5). Samples from tumours M1-M3 shared several mutations in
8 *MSH6*, including a p.Gln1155* nonsense mutation. The samples from the metastatic lesion
9 M4 carried different pathogenic variants in *MSH6*: M4a carried a p.Thr1008Ile mutation
10 previously described as recurrent in hypermutated gliomas²⁰, while M4b harboured
11 p.Gly409Glu and p.Pro1097Leu mutations. The finding of different dMMR mechanisms in
12 metastatic samples suggests that the hypermutation phenotype arose comparatively late in the
13 evolution of the tumour, and on separate occasions. To investigate this further, we examined
14 private and shared mutations from the metastases separately, and found that the mutations
15 shared by all metastatic lesions were best fitted to the flat signature seen in the primary
16 tumour samples (Supplementary figures 9A-B). Conversely, mutations common only to M1-
17 M3, as well as those unique to the two samples from M4, could largely be attributed to the
18 SBS11-like signature.

19 We further analysed whether the hypermutation signature could be attributed to *MGMT*
20 inactivation by promoter methylation, as *MGMT* is a key enzyme in the repair of alkylated
21 DNA and a mediator of resistance to alkylating agents²². This promoter region had variable
22 methylation levels across the cohort (Supplementary Table 6). There was no apparent relation
23 to hypermutation, suggesting that it was not the causative mechanism. In line with previous
24 observations in glioma²⁰, no microsatellite instability could be seen in the bulk sequencing
25 data from the hypermutated samples (Supplementary Table 4).

1
2 We point to the association between this extraordinary genomic drift fueled by alkylating
3 agents and a large change in clinical behaviour of PanNET03, in whom the disease showed
4 fast progression and high-grade transformation leading to short patient survival. This
5 transformation in tumour biology was confirmed by the increase in Ki67 index from a median
6 2,2% in primary tumour samples at baseline to a median 40% in follow-up metastatic samples
7 on PanNET03 (Figure 2A). The differences in biology between follow-up samples were also
8 captured on the DNA methylation level: follow-up samples formed a distinct group using
9 unsupervised hierarchial clustering (Figure 2D and Supplementary Figures 4E and F). These
10 differences were most pronounced in regions outside CpG Islands (mean difference 0.13 vs
11 0.04, $p < 2.2 \times 10^{-16}$ by t-test, Supplementary Figure 10). Finally, we could identify differences
12 in gene expression in follow-up samples compared to baseline samples (Supplementary
13 Figure 6A-C). This involved differences in pathways associated with cell proliferation and
14 mesenchymal to epithelial transition (Supplementary table 7), as well as neuroendocrine
15 differentiation and tissue remodelling (Supplementary table 8).

16
17 While any direct correlation to genomic variants is nearly impossible in this hypermutated
18 context, the genomic drift was clearly associated with very different biological capabilities.
19 We hypothesized that these features would change the immune landscape, and that PanNET
20 could become susceptible to immune checkpoint inhibitors that are approved across TMB
21 high metastatic cancers. We performed clustering of immune cell infiltrations using
22 CIBERSORT across PanNET samples and identified 3-4 clusters (Supplementary Figures
23 11A-B and 12). This revealed a heterogenous immune landscape in PanNET03 with
24 hypermutated metastatic samples generally immune depleted, both in the context of pan-
25 cancer samples as well as in our PanNET multi-omics cohort. Analysis with ESTIMATE

1 algorithm for tumour immune infiltration score and stromal score, showed that cluster 1 had a
2 high fraction of immune infiltration, and cluster 2 comprised a high fraction of stromal cells,
3 while cluster 3 demonstrated the highest purity (low immune score, low stromal score and
4 low ESTIMATE score). Again, this feature is in line with that of hypermutated glioblastomas
5 ²⁰.

6
7 Mismatch repair deficiency, DNA hypermutation and high-grade progression in metastatic
8 PanNET treated with alkylating chemotherapy

9 To validate the impact of alkylating chemotherapy associated dMMR, DNA hypermutation
10 and high-grade progression in PanNET, we investigated 29 post alkylating therapy samples
11 from 24 PanNETs patients (validation cohort 1). Tumour mutation burden was ≥ 50 in 8/24
12 (33%) patients, five of whom (63%) harboured mutations in *MSH6* or *MSH2* (Supplementary
13 Table 9). Five patients had two longitudinal follow-up PanNET samples characterized: TMB
14 ≥ 50 could be detected in three patients. All displayed distinct heterogeneity for both dMMR
15 and DNA hypermutation, which could only be seen in the second follow-up sample. All eight
16 patients with PanNET TMB ≥ 50 had progression from a low/intermediate to a high-grade
17 tumour (Figure 4C, Supplementary Table 9).

18 In total, the validation cohort included 16 PanNET patients with high-grade progression, 8 of
19 which had TMB ≥ 50 (50%). Among the eight patients that did not show high-grade
20 progression, none had TMB ≥ 50 (0%, (Odds ratio “infinite” (95% confidence interval 1.8-
21 “infinite” $p=0.02$).

22 Among primary PanNET samples with DNA sequencing data in the American Association for
23 Cancer Research Project GENIE repository there were only 6/599 (1%) with a TMB of ≥ 50 ,
24 all but one of these had an *MSH6* variant (Supplementary Figures 13A-D)²³⁻²⁵. Finally, we
25 were able to recover PanNET tissue from one patient with Lynch syndrome due to a

1 pathogenic germline *MSH6* variant: Whole genome sequencing revealed a TMB of 1 and no
2 trace of signature SBS11. This corroborates that SBS11 hypermutation is unlikely to occur
3 spontaneously in PanNET (Supplementary Figure 14). This is in line with previous results in
4 glioma where SBS11 primarily appears in MMR-deficient post-treatment samples²⁰.
5 Together, these experiments allow us to propose the most detailed model of PanNET
6 evolution (Figure 4D) to date. This opens a new field in PanNET research with therapy driven
7 evolution emerging as a disease hallmark with potential detrimental consequences to
8 patients.

9

10 **Discussion**

11 Metastatic PanNET is a lethal disease that frequently becomes more aggressive over time.
12 Our work highlights that metastatic PanNET is also a very dynamic disease on the genetic
13 level, with a clear association between genetic drift and more aggressive disease
14 characteristics. This insight broadens our understanding of this lethal disease, with direct
15 implications for biomarker driven research on PanNET. Further, our data indicate how
16 systemic therapy may lead to potential negative consequences for PanNET patients, with
17 alkylating chemotherapy resulting in acquired dMMR, DNA hypermutation and high grade
18 progression.

19

20 Limitations

21 This is an hypothesis generating study and has its limitations: The small sample size and
22 selection bias of the discovery cohort impedes the detection of novel metastasis-associated
23 events and evolutionary mechanisms. This limitation can largely be attributed to the rarity of
24 cases fulfilling the inclusion criteria in retrospective cohorts. Potential biases due to our
25 limited sample size are accentuated by the mixed nature of the cohort which includes both

1 formalin-fixed and paraffin-embedded core needle biopsies, as well as fresh frozen surgical
2 specimens. The core needle specimens were typically of lower tumour purity, which was
3 partly rectified by the higher depth provided by exome rather than genome sequencing.
4 Further, generalizability of our results is limited by the single center design of our study with a
5 potential for unknown center specific practises shaping tumour evolution. Future multicentre
6 prospective studies where tumour tissue is collected according to predefined protocols,
7 including autopsy may help further characterize the evolution of metastatic PanNETs.
8 Nevertheless, we made an attempt to mitigate these limitations by confirming our key finding
9 of therapy-associated DNA hypermutation in both published datasets and in a set of additional
10 metastatic PanNET samples.

11

12 Interpretation

13 Our data supports the PanNET evolutionary model where an islet cell undergoes inactivation
14 of *MEN1* as *the* tumour initiating event. The tumor may then take different evolutionary
15 trajectories, which may include inactivation of *ATRX/DAXX* followed by a complex pattern of
16 chromosomal alterations, that has associated with a more aggressive tumour biology¹¹. Finally
17 alterations involved in the mTOR signalling pathway and with chromatin regulation often
18 occur late in PanNET development, similar to observations across other cancers¹⁷. However,
19 the most critical finding of this study is how therapy driven tumour evolution may lead to
20 negative consequences for PanNET patients, with alkylating chemotherapy beeing associated
21 with acquired dMMR, DNA hypermutation and high-grade progression. While this finding is
22 strongly supported by unpublished data on PanNETs²⁶ it is a well-documented phenomenon
23 in gliomas²⁰. Here the selective pressure exerted by alkylating chemotherapy selects dMMR
24 clones, and hypermutation is induced by the dual presence of dMMR and alkylating agents²⁰.
25 This is likely due to the inability of dMMR cells to repair the damage incurred by DNA

1 alkylation. As found in glioma, our study suggests that these mechanisms leads to a more
2 aggressive PanNET. Although, future studies is needed to confirm these findings.

3
4 Another important question is whether treatment-related hypermutation renders the
5 metastases susceptible to immune checkpoint inhibitors. Although limited data suggests that
6 this is not the case in glioma²⁰, experimental evidence implies that the lack of immune
7 activation in hypermutated cases is due to the central nervous system microenvironment²⁷.

8 While increased intratumoural heterogeneity is likely to reduce tumour immunogenicity²⁸, an
9 initial analysis of the ARETHUSA trial, in which patients with mismatch repair-proficient
10 colorectal carcinoma are treated with temozolomide to induce hypermutation, followed by
11 pembrolizumab, suggests that a subset of patients may achieve disease stabilization with this
12 strategy²¹. Evaluation of immunotherapy in the context of PanNETs with treatment-induced
13 hypermutation may thus be warranted^{29,30}. Another hypothesis generated by our data is that
14 slowly proliferating PanNET should not be prioritized for DNA damaging treatments that
15 may accelerate tumour evolution towards more aggressive disease characteristics. Instead
16 patients may have better long-term outcome if surgery and/or somatostatin analogue based
17 therapies are prioritized.

18
19 Our results also contextualizes how on-going research efforts in using genetic biomarkers to
20 direct care of PanNET patients should take into account genetic heterogeneity of certain
21 loci³¹: While *MEN1* aberrations are to be expected to be shared among all tumour cells,
22 remaining PanNET driver events may indeed exhibit relevant heterogeneity that cannot be
23 fully characterized using archived tissue or even a fresh tumour biopsy. We recommend that
24 timely tissue acquisition should be required for inclusion in biomarker driven trials ,and that
25 longitudinal samples are studied to fully describe how new PanNET therapies may shape the

1 biology of this disease. As for today, those PanNET patients that experience high grade
2 progression after alkylating chemotherapy could be considered for TMB analysis, especially
3 in countries where this result may provide additional treatment options. Finally our data
4 strongly emphasize the need for novel and emerging methods, including blood based methods
5 such as liquid biopsy as well as functional imaging that may both be able to provide real-time
6 whole-body characterization of metastatic PanNET.

1 **Online Methods**

2 Ethics Statement

3 Ethical approval was granted through DNRs 2018/401, 2015/544/2 and 2012/422. This study
4 was conducted accordingly to the Helsinki declaration.

5

6 Discovery Cohort

7 Four different tissue collections at the Departments of Endocrine Oncology, Endocrine
8 Surgery and Pathology as well as the Uppsala “U-CAN” collection³² were scrutinised to
9 identify cases fulfilling the following criteria: patients with frozen panNET tissue samples
10 available from metachronous time points. At least one tumour sample had to be from a
11 metastatic lesion. Finally, each case had to have tissue or DNA from non-tumoural cells
12 available. From the identified patients up to 3 tumour samples were acquired from each
13 unique tumour lesion depending on availability. Tissue sections for histopathology were
14 subjected to haematoxylin and eosin staining as well as MIB-1 immunostaining before
15 examination accordingly to ENETS/WHO criteria by two expert endocrine pathologists (JB
16 and CCJ)³³.

17

18 Pan-molecular characterisation of multi-region tumour samples

19 Tumour purity cut-off were set to 50% (specimens from surgical resections) and 30% (core
20 needle biopsy) to proceed with nucleic acid extraction. The experimental strategy is
21 overviewed in Figure 1. Samples were prepared so that DNA and RNA were obtained from
22 the same tissue sections (surgical samples) or from neighbouring sections (core needle). All
23 samples were subjected to pan-genomic characterisation with whole genome (surgical
24 samples and corresponding non-tumoural tissue) or exome (core needle biopsies and
25 corresponding non-tumoural tissue) sequencing. Further, surgical samples also underwent

1 total RNA sequencing and were characterised using the Illumina EPIC DNA methylation
2 array.

3

4 Bioinformatics analysis

5 We aimed to perform a comprehensive characterisation of PanNET biology with particular
6 focus on tumour intra- and inter heterogeneity. Experimental methods are described in full
7 detail in the supplementary appendix. Briefly, mutation detection was performed using the
8 Sarek pipeline, copy number analysis with ASCAT and ScIust, while RNA-seq analysis was
9 performed using the nf-core-rnaseq pipeline and DNA methylation array data analysed using
10 minfi. To put findings into perspective we compared all samples within the discovery cohort
11 to each other. When appropriate we also analysed all samples within the discovery cohort
12 from a pan-cancer perspective using data from the Cancer Genome Atlas (TCGA)³⁴ as well as
13 a separate cohort of gastroenteropancreatic neuroendocrine tumours³⁵.

14

15 Validation cohorts

16 Three validation experiments using different cohorts were conducted: In validation cohort 1
17 metastatic PanNET patients treated at Uppsala University Hospital with tumour samples
18 available after treatment with alkylating chemotherapy were studied using targeted next
19 generation sequencing with the Genomics Medicine Sweden (GMS)560 panel. In validation
20 cohort 2 we aimed to describe the presence of hypermutation and lesions in *MSH2*, *MSH6*,
21 *MLH1*, or *PMS2* in an unselected PanNET cohort by using a public DNA sequencing dataset
22 of primary and metastatic PanNETs: American Association for Cancer Research Project
23 Genomics Evidence Neoplasia Information Exchange (GENIE, <https://genie.cbioportal.org>)
24 ²³⁻²⁵. Finally, in validation cohort 3 we aimed to describe the mutational landscape of lynch
25 syndrome associated PanNETs, such patients with tumour tissue available at Uppsala

1 University Hospital were identified. Here tissues were characterized by Whole Genome
2 Sequencing using the same approach as previously described.
3
4 Statistical Analyses
5 Nominal data were presented as number of patients and percentages. Groups were compared
6 by using Odds Ratio and Fisher's exact test through Prism 10.1 (GraphPad Software Inc). P
7 values <0.05 were considered as statistically significant. Statistical analyses of methylation
8 and gene expression data were performed in R as described in the Supplementary Methods.

1 **Acknowledgements**

2 The authors acknowledge the important contributions made by the included patients as well as
3 all collaborators, funders and those maintaining research infrastructure:

4 Joakim Cronas research position is funded by Cancerfonden. This work was supported by
5 grants from Cancerfonden, the European Neuroendocrine Tumor Society, Lions
6 Cancerforskningsfond Uppsala, Åke Wibergs Stiftelse and Söderbergs stiftelser.

7 Sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. The facility is
8 part of the National Genomics Infrastructure (NGI) Sweden and Science for Life Laboratory.

9 The SNP&SEQ Platform is supported by the Swedish Research Council and the Knut and
10 Alice Wallenberg Foundation.

11 Part of the material was collected with support of U-CAN, through Uppsala Biobank and the
12 Department of Clinical Pathology, Uppsala University Hospital.

13 The computations and data handling were enabled by resources in project sens2019036
14 provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) at
15 UPPMAX, funded by the Swedish Research Council through grant agreement no. 2022-
16 06725.

17 The authors acknowledge Clinical Genomics Uppsala, Science for Life Laboratory,
18 Department of Immunology, Genetics and Pathology, Uppsala University, Sweden for
19 providing assistance with Exome Sequencing and Targeted Sequencing (GMS560) including
20 sample preparation, library preparation, bioinformatics and data interpretation.

21 This work was supported, by the Intramural Research Program of the National Institutes of
22 Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

23 The authors would also like to acknowledge the American Association for Cancer Research
24 and its financial and material support in the development of the AACR Project GENIE
25 repository, as well as members of the consortium for their commitment to data sharing.

1 **Data availability**

2 Access to the sensitive raw data can be requested through <https://www.u-can.uu.se/>. All
3 additional data can be obtained from the corresponding author upon reasonable request.

4

5 **Code availability**

6 The data analyses presented in this paper were performed using publicly available software as
7 detailed in the Methods and Supplementary methods. Key scripts to reproduce figures and
8 analyses have been deposited in a github repository
9 (https://github.com/sabackman/PanNET_Evolution).

1 References

- 2 1. Auernhammer, C.J. *et al.* Advanced neuroendocrine tumours of the small intestine and
3 pancreas: clinical developments, controversies, and future strategies. *Lancet Diabetes*
4 *Endocrinol* **6**, 404-415 (2018).
- 5 2. Dasari, A. *et al.* Trends in the Incidence, Prevalence, and Survival Outcomes in
6 Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol* **3**, 1335-
7 1342 (2017).
- 8 3. Modlin, I.M. *et al.* Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol* **9**,
9 61-72 (2008).
- 10 4. Tang, L.H. *et al.* Well-Differentiated Neuroendocrine Tumors with a Morphologically
11 Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated
12 Neuroendocrine Carcinomas. *Clin Cancer Res* **22**, 1011-7 (2016).
- 13 5. Crona, J. *et al.* Multiple and Secondary Hormone Secretion in Patients With
14 Metastatic Pancreatic Neuroendocrine Tumours. *J Clin Endocrinol Metab* **101**, 445-52
15 (2016).
- 16 6. de Mestier, L. *et al.* Metachronous hormonal syndromes in patients with pancreatic
17 neuroendocrine tumors: a case-series study. *Ann Intern Med* **162**, 682-9 (2015).
- 18 7. Botling, J. *et al.* High-Grade Progression Confers Poor Survival in Pancreatic
19 Neuroendocrine Tumors. *Neuroendocrinology* **110**, 891-898 (2020).
- 20 8. Scarpa, A. *et al.* Whole-genome landscape of pancreatic neuroendocrine tumours.
21 *Nature* **543**, 65-71 (2017).
- 22 9. Crona, J. & Skogseid, B. GEP- NETS UPDATE: Genetics of neuroendocrine tumors.
23 *Eur J Endocrinol* **174**, R275-90 (2016).
- 24 10. de Wilde, R.F. *et al.* Loss of ATRX or DAXX expression and concomitant acquisition
25 of the alternative lengthening of telomeres phenotype are late events in a small subset
26 of MEN-1 syndrome pancreatic neuroendocrine tumors. *Mod Pathol* **25**, 1033-9
27 (2012).
- 28 11. Marinoni, I. *et al.* Loss of DAXX and ATRX are associated with chromosome
29 instability and reduced survival of patients with pancreatic neuroendocrine tumors.
30 *Gastroenterology* **146**, 453-60.e5 (2014).
- 31 12. Sadanandam, A. *et al.* A Cross-Species Analysis in Pancreatic Neuroendocrine
32 Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic,
33 Developmental, and Metabolic Characteristics. *Cancer Discov* **5**, 1296-313 (2015).
- 34 13. Roy, S. *et al.* Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates
35 With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival
36 Times. *Gastroenterology* **154**, 2060-2063.e8 (2018).
- 37 14. Raj, N. *et al.* Real-Time Genomic Characterization of Metastatic Pancreatic
38 Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential
39 Germline Actionability. *JCO Precision Oncology*, 1-18 (2018).
- 40 15. Xu, M. *et al.* Evolutionary Trajectories of Primary and Metastatic Pancreatic
41 Neuroendocrine Tumors Based on Genomic Variations. *Genes (Basel)* **13**(2022).
- 42 16. Quevedo, R. *et al.* Centromeric cohesion failure invokes a conserved choreography of
43 chromosomal mis-segregations in pancreatic neuroendocrine tumor. *Genome Med* **12**,
44 38 (2020).
- 45 17. McGranahan, N. *et al.* Clonal status of actionable driver events and the timing of
46 mutational processes in cancer evolution. *Sci Transl Med* **7**, 283ra54 (2015).
- 47 18. Falconi, M. *et al.* ENETS Consensus Guidelines Update for the Management of
48 Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional
49 Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* **103**, 153-71 (2016).

- 1 19. Alexandrov, L.B. *et al.* The repertoire of mutational signatures in human cancer.
2 *Nature* **578**, 94-101 (2020).
- 3 20. Touat, M. *et al.* Mechanisms and therapeutic implications of hypermutation in
4 gliomas. *Nature* **580**, 517-523 (2020).
- 5 21. Crisafulli, G. *et al.* Temozolomide Treatment Alters Mismatch Repair and Boosts
6 Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. *Cancer Discov*
7 **12**, 1656-1675 (2022).
- 8 22. Hegi, M.E. *et al.* MGMT gene silencing and benefit from temozolomide in
9 glioblastoma. *N Engl J Med.* **352**, 997-1003. (2005).
- 10 23. Cerami, E. *et al.* The cBio cancer genomics portal: an open platform for exploring
11 multidimensional cancer genomics data. *Cancer Discov* **2**, 401-4 (2012).
- 12 24. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles
13 using the cBioPortal. *Sci Signal* **6**, p11 (2013).
- 14 25. AACR Project GENIE: Powering Precision Medicine through an International
15 Consortium. *Cancer Discov* **7**, 818-831 (2017).
- 16 26. de Mestier du Bourg, L. *et al.* 1182O Temozolomide treatment induces an MMR-
17 dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine
18 tumors. *Annals of Oncology* **34**, S701 (2023).
- 19 27. Daniel, P. *et al.* Detection of temozolomide-induced hypermutation and response to
20 PD-1 checkpoint inhibitor in recurrent glioblastoma. *Neurooncol Adv* **4**, vdac076
21 (2022).
- 22 28. McGranahan, N. *et al.* Clonal neoantigens elicit T cell immunoreactivity and
23 sensitivity to immune checkpoint blockade. *Science* **351**, 1463-9 (2016).
- 24 29. Sun, F. *et al.* Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated
25 Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. *JCO Precis*
26 *Oncol* **6**, e2200009 (2022).
- 27 30. Moog, S. *et al.* Alkylating Agent-Induced High Tumor Mutational Burden in
28 Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case
29 Reports. *Thyroid* (2023).
- 30 31. Owen, D.H. *et al.* A Phase II Clinical Trial of Nivolumab and Temozolomide for
31 Neuroendocrine Neoplasms. *Clin Cancer Res* **29**, 731-741 (2023).
- 32 32. Glimelius, B. *et al.* U-CAN: a prospective longitudinal collection of biomaterials and
33 clinical information from adult cancer patients in Sweden. *Acta Oncol* **57**, 187-194
34 (2018).
- 35 33. Lloyd, R.V., Osamura, R.Y., Kloppel, G. & Rosai, J. *WHO classification of tumours:
36 pathology and genetics of tumours of endocrine organs*, (Lyon: IARC; 2017, 2017).
- 37 34. Hoadley, K.A. *et al.* Cell-of-Origin Patterns Dominate the Molecular Classification of
38 10,000 Tumors from 33 Types of Cancer. *Cell* **173**, 291-304.e6 (2018).
- 39 35. Alvarez, M.J. *et al.* A precision oncology approach to the pharmacological targeting of
40 mechanistic dependencies in neuroendocrine tumors. *Nat Genet* **50**, 979-989 (2018).

41
42
43
44
45

1 **Figure legends**

2 Figure 1 – a) Overview of experimental strategy. Created with BioRender.com. b) Summary
3 of main findings across the cohort. PanNET samples were annotated for location (P, Primary
4 tumour; M, metastasis), Tumour lesion number (1-4) and Sample number from each
5 individual tumour lesion (a-c). Abbreviations: LNM, lymph node metastasis; WES, Whole
6 exome sequencing; and WGS, Whole genome sequencing.

7 Figure 2 – a) Treatment timeline for patient PanNET03. b) Representative images of Ki67
8 staining of primary and metastatic samples P1a and M3a demonstrates high-grade
9 transformation with Ki67 rising from 1% to 75%. c) Phylogenetic tree of bulk samples from
10 PanNET03. PanNET samples were annotated for location (P, Primary tumour; M, metastasis),
11 Tumour lesion number (1-4) and Sample number from each individual tumour lesion (a-c).
12 The metachronous metastatic samples form an outgroup and convergent evolution of the
13 *ATRX/DAXX* is seen. The dotted lines have been shortened for visualization purposes. d) The
14 metastatic samples share a distinct DNA methylation pattern. e) Subclonal reconstruction with
15 PyClone-VI reveals separate dominant clones shared by the primary tumour and metastatic
16 lesion samples respectively. Abbreviations: CCF, Cancer cell fraction; and STZ,
17 streptozocin.

18 Figure 3 – a-c) Timelines, phylogenetic trees, and DNA methylation heatmaps for PanNET01,
19 PanNET02 and PanNET04. PanNET samples were annotated for location (P, Primary tumour;
20 M, metastasis), Tumour lesion number (1-4) and Sample number from each individual tumour
21 lesion (a-c). Groupings based on DNA methylation and on somatic mutations are noted to
22 show the same patterns. For PanNET04, the lengths of some branches have been increased for
23 visualization purposes. The corresponding raw trees are available in the supplementary
24 material. Abbreviations: α -INF: Alfa-interferon; SSA, somatostatin analogue; STZ,
25 streptozocin.

1 Figure 4 – a) Metastatic tumours from PanNET03 exhibit a hypermutation phenotype
2 attributable to a unique mutation signature. PanNET samples were annotated for location (P,
3 Primary tumour; M, metastasis), Tumour lesion number (1-4) and Sample number from each
4 individual tumour lesion (a-c). The presence of this signature correlates strongly with the
5 presence of pathogenic variants in *MSH6* and is unrelated to microsatellite instability as
6 measured by MSIsensor b) De novo mutation signature extraction of genome sequencing
7 samples identifies a signature dominated by C>T transversions as well as a "flat" signature. c)
8 Tumour mutation burden, alkylation-related mutation signature and mutation status of
9 mismatch repair genes among PanNET with and without high-grade progression. D) Proposed
10 model for PanNET evolutionary history including the influence of alkylating chemotherapy.
11 Abbreviations: dMMR, mismatch repair deficiency; TMB, Tumour mutation burden; VAF,
12 Variant allele frequency.

13

14 **Supplementary figure legends**

15 Throughout supplementary figures PanNET samples were annotated for location (P, Primary
16 tumour; M, metastasis), Tumour lesion number (1-4) and Sample number from each
17 individual tumour lesion (a-c).

18 Supplementary figure 1) Summary of treatment timelines and sample collection for patients
19 included in the discovery cohort. Abbreviations: α -INF, Alfa-interferon; PRRT, Lu177-

20 DOTATATE; SSA, Somatostatin; STZ: Streptozotocin analogue. α -INF: Alfa-interferon

21 Supplementary figure 2 A-F) Copy number profiles of samples from the discovery cohort.

22 Supplementary figure 3 A-F) Raw phylogenetic trees based on small mutation data for
23 samples from the discovery cohort.

24 Supplementary figure 4) DNA methylation heatmaps and phyloepigenetic trees for patients

25 PanNET01 (A-B), PanNET02 (C-D), PanNET0 (E-F) and PanNET04 (G-H). In the

1 phyloepigenetic trees blue branches denote primary tumour samples and red branches
2 metastatic lesions. Follow-up samples are marked in grey.
3 Supplementary figure 5) DNA methylation heatmap of all samples with available data.
4 Samples cluster based on patient of origin.
5 Supplementary figure 6 a) Gene ontologies enriched among genes upregulated in follow-up
6 samples from PanNET03. b) Gene ontologies enriched among genes downregulated in
7 follow-up samples from PanNET03. c) Gene expression heatmap of all fresh-frozen samples.
8 Supplementary figure 7) Clone distribution plots for patients PanNET01; a) PanNET02, b)
9 and c) PanNET03. In PanNET01, the metastases share a clone (Clone 3) not present in
10 primary tumours. In PanNET02, the primary tumours share Clone 2, not present in the
11 metastatic sample potentially suggesting early metastatic seeding. In PanNET04 P1b/P1c
12 share a clone with M2a/M2b, while P1a share a clone with M1a/M1b while M3 does not
13 contain either of these clones, suggestive of multiple separate metastatic seeding events .
14 Abbreviations: CCF, Cancer cell fraction.
15 Supplementary figure 8 a) Estimates used for deciding the number of mutation signatures to
16 use for *de novo* mutation signature detection. Based on this plot extractions of 2-4 signatures
17 were trialled. b-g) Mutation signatures and contributions using NMF extraction of 2 (B-C), 3
18 (D-E) and 4 (F-G) signatures. H) Estimated contributions of COSMIC v3 cancer mutation
19 signatures identifies SBS11 as a strong contributor in the metastatic samples from PanNET03.
20 I) Cosine similarity between raw and reconstructed mutation patterns related to (H).
21 Supplementary figure 9) Mutations shared between all metastatic samples from PanNET03
22 have a similar mutation signature to those found in the primary tumour samples, while
23 mutations shared by M4a and M4b, as well as those shared by M1-M3 are dominated by the
24 C>T SBS11-like signature.

1 Supplementary figure 10) DNA methylation difference between baseline and follow-up
2 samples is greater in non-CpG-island sites.

3 Supplementary figure 11) Pan-cancer clustering of Immune function enrichment in a cohort of
4 24 tumour types. Abbreviations: GEPNET, Gastroenteropancreatic neuroendocrine tumours;
5 PCPG, Pheochromocytoma and Paraganglioma; PanNET, Pancreatic neuroendocrine tumour
6 and TCGA, the Cancer Genome Atlas.


7 Supplementary figure 12) Clustering of immune gene set enrichments (GSVA) across
8 pancreatic tumour samples identified 3 clusters.

9 Supplementary figure 13) Genomic characteristics of 574 pancreatic NETs in the AACR
10 GENIE cohort, a) 278 primary tumours, c) 289 metastases, and d) 8 *MSH6*-mutated
11 metastases.


12 Supplementary figure 14) No evidence of significant contribution of SBS11 in a PanNET
13 from a patient with Lynch syndrome.






14 Supplementary figure 15) Fraction of heterozygous SNPs with the same allele retained on
15 chromosomes affected by cnLOH events in (A) PanNET03 and (B) PanNET04. For
16 PanNET03 chromosomes 1-3, 6, 8-11, 15-16 and 21-22 were included. For PanNET04
17 chromosomes 1-3, 6, 8, 10-11, 15-16, 18 and 21-22 were included. Abbreviations: LOH, Loss
18 of heterozygosity.









A






B



A**B****C****D****E**

A**B****C**

A**B****C****D**